News

After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...
Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Medi-Cal coverage of weight loss drugs on chopping block under governor’s proposal
Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...
MarketWatch4d
CVS Health’s Aetna to exit Obamacare business, boost Wegovy access
Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...
Press of Atlantic City2d
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
The Pantagraph5d
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...
The Columbian2d
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
More than three-quarters of patients taking both drugs reported at least one side effect, mostly mild to moderate gastrointestinal issues ... This week, CVS Health said Wegovy will become the ...